About SEngine Precision Medicine
SEngine Precision Medicine is a private company based in Seattle, Washington. It has reported $9,245,984 raised in two offerings on Form D since September 2018. Its chief executive is Carla Grandori.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2023 | Mar 10, 2023 | $600,000of $3.5M target | 2 | $300K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Aug 29, 2018 | Sep 12, 2018amended Oct 9, 2019 | $8,645,984of $13.5M target | 40 | $216K | Equity, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $9,245,984 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on SEngine Precision Medicine's Form D filed Mar 10, 2023.
CK
Christopher Kemp
Executive officer and promoter
PP
Pablo Prichard
Director
TH
Tony Hsu
Executive officer
EB
Elliott Burkland
Director
CG
Carla Grandori
President and CEO, director
Earlier filings also listed Ulrich Mueller (executive officer, last listed Oct 2019), Tom Neary (executive officer, last listed Oct 2019), Lee Hartwell (director, last listed Oct 2019) and Jesse Ferrer (director, last listed Oct 2019).